Malta - English - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - film-coated tablet - deferasirox 90 mg - all other therapeutic products

Malta - English - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - film-coated tablet - deferasirox 180 mg - all other therapeutic products

Malta - English - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - film-coated tablet - deferasirox 360 mg - all other therapeutic products

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: hyprolose; dibasic sodium phosphate; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; sodium lauryl sulfate; hydrogenated castor oil; magnesium stearate - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 250 mg - tablet, dispersible - excipient ingredients: crospovidone; sodium lauryl sulfate; hydrogenated castor oil; hypromellose; microcrystalline cellulose; hyprolose; colloidal anhydrous silica; magnesium stearate; dibasic sodium phosphate - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: hyprolose; crospovidone; hydrogenated castor oil; sodium lauryl sulfate; magnesium stearate; microcrystalline cellulose; hypromellose; dibasic sodium phosphate; colloidal anhydrous silica - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - deferasirox, quantity: 125 mg - tablet, dispersible - excipient ingredients: colloidal anhydrous silica; crospovidone; hyprolose; microcrystalline cellulose; hydrogenated castor oil; hypromellose; dibasic sodium phosphate; magnesium stearate; sodium lauryl sulfate - deferasirox is indicated in the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. it is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.